J Gynecol Oncol.  2025 Jan;36(1):e69. 10.3802/jgo.2025.36.e69.

Clinical practice guidelines for ovarian cancer: an update to the Korean Society of Gynecologic Oncology guidelines

Affiliations
  • 1Department of Obstetrics and Gynecology, Inha University Hospital, Inha University College of Medicine, Incheon, Korea
  • 2Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea
  • 3Department of Obstetrics and Gynecology, School of Medicine, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Korea
  • 4Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea
  • 5Department of Obstetrics and Gynecology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea
  • 6Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  • 7Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 8Department of Obstetrics and Gynecology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Korea
  • 9Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea
  • 10Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea

Abstract

We updated the Korean Society of Gynecologic Oncology (KSGO) practice guideline for the management of ovarian cancer as version 5.1. The ovarian cancer guideline team of the KSGO published announced the fifth version (version 5.0) of its clinical practice guidelines for the management of ovarian cancer in December 2023. In version 5.0, the selection of the key questions and the systematic reviews were based on the data available up to December 2022. Therefore, we updated the guidelines version 5.0 with newly accumulated clinical data and added 5 new key questions reflecting the latest insights in the field of ovarian cancer between 2023 and 2024. For each question, recommendation was provided together with corresponding level of evidence and grade of recommendation, all established through expert consensus.

Keyword

Hyperthermic Intraperitoneal Chemotherapy; Risk-educing Salpingo-oophorectomy; Poly(ADP-ribose) Polymerase (PARP) Inhibitor; Mirvetuximab Soravtansine; Trastuzumab Deruxtecan; Practice Guideline; Ovarian Neoplasms
Full Text Links
  • JGO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr